Retevmo 80 mg

$8,999.00

this product is available by prescription only

Clear Filters

Licensed partner pharmacies

Tracked international shipping

Refund within 28 days

Secure, encrypted checkout

Standard-Dose RET Inhibitor Capsule for the Majority of Patients

Retevmo 80 mg is the primary capsule strength for selpercatinib, used in the standard 160 mg twice-daily regimen for patients weighing 50 kg or more. This is the dose evaluated in the pivotal LIBRETTO-001 trial, where it demonstrated robust clinical responses across RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. Each capsule meets strict oncology manufacturing standards. A confirmed RET gene alteration via approved companion diagnostic testing is required before prescribing.

Clinically Proven Tumor Control Across Multiple RET-Altered Cancers

At the 80 mg-based regimen, selpercatinib delivers its full clinical potential — blocking oncogenic RET signaling with high selectivity, achieving objective response rates of up to 84% in treatment-naive RET fusion-positive NSCLC patients in the LIBRETTO-001 trial. Activity is maintained across RET fusions and RET activating mutations. CNS penetrance provides intracranial efficacy for patients with brain metastases. Reduced off-target kinase inhibition means a more manageable tolerability profile compared to earlier multikinase inhibitors.

160 mg Twice Daily for Patients 50 kg or More — Oncology Specialist Required

The recommended dose for patients weighing 50 kg or more is 160 mg twice daily — two 80 mg capsules per dose, with or without food. Total daily dose is 320 mg. Capsules must be swallowed whole. Dose modifications apply for strong CYP3A4 inhibitors or inducers, hepatic impairment, and specified adverse reactions. Concurrent use of acid-reducing agents should be managed per prescribing guidance. Treatment is initiated and managed by an oncology specialist throughout the course of therapy.

  • CAS:
  • Chemical Formula:
  • Molecular Weight:
  • Peptide Sequence:
  • Synonyms:

Frequently bought together

Related products

Order Retevmo 80 mg
Reliable Research-Grade Retevmo 80 mg Peptide with Verified Laboratory Quality

Buy Retevmo 80 mg

The Pivotal Trial Dose — Available Through Elivena’s Oncology Supply

Retevmo 80 mg is the cornerstone of the selpercatinib treatment regimen. The 160 mg twice-daily dose, built around two 80 mg capsules, is the regimen on which all of the pivotal clinical evidence is based. For treatment-naive patients with RET fusion-positive NSCLC, this regimen produced an objective response rate exceeding 80% in LIBRETTO-001. For patients with RET-mutant MTC, response rates in both previously treated and treatment-naive cohorts were similarly strong. Selpercatinib’s selectivity for RET distinguishes it from the multikinase inhibitors cabozantinib and vandetanib, which were previously used in RET-altered cancers but produced significant VEGFR2-mediated toxicities. For patients who progressed on or were intolerant of these agents, Retevmo offers a well-tolerated alternative with superior clinical activity. For patients weighing less than 50 kg, Retevmo 40 mg is the appropriate capsule strength, used at a dose of 120 mg twice daily. Both strengths are available through Elivena. Browse the Oncology category for additional precision oncology products supplied from Canada. Elivena supplies Retevmo directly from licensed Canadian sources with full traceability and product authenticity verification. Our oncology account team is equipped to support providers, clinics, and distributors with documentation, bulk ordering, and ongoing supply coordination. Access to precision oncology therapies must be dependable. Delays in treatment supply can have direct clinical consequences. Elivena is built to be the reliable link in your supply chain — handling the logistics so your focus stays on patient care. Place your order at elivena.com or contact our oncology account team today for tailored supply support.

Frequently Asked Questions

What is Retevmo 80 mg used for?
What were the results of the LIBRETTO-001 trial?
How does Retevmo differ from older RET-targeting drugs?
Can Retevmo treat brain metastases?